Monday, November 12, 2007

ChemoCentryx Files For IPO

Mountain View-based ChemoCentryx said Friday in a filing with the SEC that it is looking to raise up to $57.5M in an IPO on the Nasdaq Global Market. The firm is focused on discovery, development and commercialization of orally-administered small molecule therapeutics. The IPO is being underwritten by Credit Suisse, Cowen and Company, Leerink Swann, and Lazard Capital Markets. The firm is venture backed by GlaxoSmithKline, Techne Corporation, OrbiMed, HBM BioVentures, Alta Partners, and HealthCap. The firm is looking to trade under the symbol CCXI.